Sherry H-Y Chou1, Claudia S Robertson. 1. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA, schou1@partners.org.
Abstract
BACKGROUND: Molecular biomarkers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction. Urgent need for high-fidelity biomarkers in neurocritical care has resulted in numerous studies reporting potential candidate biomarkers. METHODS: We performed an electronic literature search and systematic review of English language articles on cellular/molecular biomarkers associated with outcome and with disease-specific secondary complications in adult patients with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), and post-cardiac arrest hypoxic ischemic encephalopathic injuries (HIE). RESULTS: A total of 135 articles were included. Though a wide variety of potential biomarkers have been identified, only neuron-specific enolase has been validated in large cohorts and shows 100% specificity for poor outcome prediction in HIE patients not treated with therapeutic hypothermia. There are many promising candidate blood and CSF biomarkers in SAH, AIS, ICH, and TBI, but none yet meets criteria for routine clinical use. CONCLUSION: Current studies vary significantly in patient selection, biosample collection/processing, and biomarker measurement protocols, thereby limiting the generalizability of overall results. Future large prospective studies with standardized treatment, biosample collection, and biomarker measurement and validation protocols are necessary to identify high-fidelity biomarkers in neurocritical care.
BACKGROUND: Molecular biomarkers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction. Urgent need for high-fidelity biomarkers in neurocritical care has resulted in numerous studies reporting potential candidate biomarkers. METHODS: We performed an electronic literature search and systematic review of English language articles on cellular/molecular biomarkers associated with outcome and with disease-specific secondary complications in adult patients with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), and post-cardiac arrest hypoxic ischemic encephalopathic injuries (HIE). RESULTS: A total of 135 articles were included. Though a wide variety of potential biomarkers have been identified, only neuron-specific enolase has been validated in large cohorts and shows 100% specificity for poor outcome prediction in HIE patients not treated with therapeutic hypothermia. There are many promising candidate blood and CSF biomarkers in SAH, AIS, ICH, and TBI, but none yet meets criteria for routine clinical use. CONCLUSION: Current studies vary significantly in patient selection, biosample collection/processing, and biomarker measurement protocols, thereby limiting the generalizability of overall results. Future large prospective studies with standardized treatment, biosample collection, and biomarker measurement and validation protocols are necessary to identify high-fidelity biomarkers in neurocritical care.
Authors: Khalid A Hanafy; Bartosz Grobelny; Luis Fernandez; Pedro Kurtz; E S Connolly; Stephan A Mayer; Christian Schindler; Neeraj Badjatia Journal: J Neurol Sci Date: 2010-01-27 Impact factor: 3.181
Authors: Matthew J McGirt; John R Lynch; Robert Blessing; David S Warner; Allan H Friedman; Daniel T Laskowitz Journal: Neurosurgery Date: 2002-11 Impact factor: 4.654
Authors: Erwin Chiquete; José L Ruiz-Sandoval; Luis M Murillo-Bonilla; Antonio Arauz; Diego R Orozco-Valera; Ana Ochoa-Guzmán; Jorge Villarreal-Careaga; Carolina León-Jiménez; Fernando Barinagarrementeria; Alma Ramos-Moreno; Carlos Cantú-Brito Journal: Cerebrovasc Dis Date: 2013-02-22 Impact factor: 2.762
Authors: K Nylén; M Ost; L Z Csajbok; I Nilsson; C Hall; K Blennow; B Nellgård; L Rosengren Journal: Acta Neurochir (Wien) Date: 2008-01-14 Impact factor: 2.216
Authors: Christian Foerch; Bettina Otto; Oliver C Singer; Tobias Neumann-Haefelin; Bernard Yan; Joachim Berkefeld; Helmuth Steinmetz; Matthias Sitzer Journal: Stroke Date: 2004-08-05 Impact factor: 7.914
Authors: Matthew E Peters; Vani Rao; Kathleen T Bechtold; Durga Roy; Haris I Sair; Jeannie-Marie Leoutsakos; Ramon Diaz-Arrastia; Robert D Stevens; D Scott Batty; Hayley Falk; Christopher Fernandez; Uju Ofoche; Alexandra Vassila; Anna J Hall; Braden Anderson; Edward Bessman; Constantine G Lyketsos; Allen D Everett; Jennifer Van Eyk; Frederick K Korley Journal: Brain Inj Date: 2017-01-31 Impact factor: 2.311
Authors: Alicia K Au; Michael J Bell; Ericka L Fink; Rajesh K Aneja; Patrick M Kochanek; Robert S B Clark Journal: Neurocrit Care Date: 2018-02 Impact factor: 3.210
Authors: Julia Halford; Sean Shen; Kyohei Itamura; Jaclynn Levine; Albert C Chong; Gregg Czerwieniec; Thomas C Glenn; David A Hovda; Paul Vespa; Ross Bullock; W Dalton Dietrich; Stefania Mondello; Joseph A Loo; Ina-Beate Wanner Journal: J Cereb Blood Flow Metab Date: 2017-08-17 Impact factor: 6.200
Authors: Lina Bergman; Pablo Torres-Vergara; Jeffrey Penny; Johan Wikström; Maria Nelander; Jose Leon; Mary Tolcher; James M Roberts; Anna-Karin Wikström; Carlos Escudero Journal: Curr Hypertens Rep Date: 2019-08-02 Impact factor: 5.369
Authors: Fang Yu; Aisha Saand; Changhong Xing; Jong Woo Lee; Liangge Hsu; Octavia P Palmer; Vanessa Jackson; Lu Tang; MingMing Ning; Rose Du; Patrick M Kochanek; Eng H Lo; Sherry H-Y Chou Journal: J Cereb Blood Flow Metab Date: 2021-05-05 Impact factor: 6.200